Cleerly ISCHEMIA vs VX1+

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Cleerly ISCHEMIA

by Cleerly

VX1+

by Volta Medical

AI Verdict

Cleerly ISCHEMIA is designed for non-invasive diagnosis and treatment planning of coronary artery disease through CCTA scan analysis. In contrast, VX1+ provides real-time AI-driven assistance to electrophysiologists during invasive cardiac ablation procedures for atrial fibrillation and tachycardia. While both are cardiology AI tools, their distinct focus on diagnostic imaging for coronary disease versus intra-procedural guidance for arrhythmias means they address different clinical needs and stages of care.

Choose Cleerly ISCHEMIA if…

Choose Cleerly ISCHEMIA if you need a non-invasive, AI-powered assessment of coronary artery disease to determine the likelihood of ischemia and characterize plaque burden. This tool is ideal for pre-procedural planning, risk stratification, and guiding medical management for patients with suspected or known heart disease based on CCTA scans.

View Cleerly ISCHEMIA →

Choose VX1+ if…

Choose VX1+ if you are an electrophysiologist performing cardiac ablation procedures for atrial fibrillation or tachycardia and require real-time, AI-driven identification of abnormal electrograms. This software is designed to enhance procedural efficiency and effectiveness by assisting in the precise targeting of ablation sites during live procedures.

View VX1+ →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Cleerly ISCHEMIA	VX1+
Deployment	Web-based solution	Software, compatible with most multipolar catheters and mapping technologies used in operating rooms or electrophysiology labs.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

VX1+

VX1+ emphasizes a 'simple user interface with color coding' and real-time assistance during live procedures, suggesting a design optimized for immediate and intuitive use in a high-pressure clinical environment. Cleerly ISCHEMIA, while offering 'comprehensive interactive web-based reports,' focuses more on post-analysis review rather than real-time procedural interaction.

Clinical Value

Tie

Both tools offer significant clinical value by addressing critical needs in cardiology. Cleerly ISCHEMIA provides non-invasive diagnostic insights for heart disease, potentially guiding earlier treatment decisions. VX1+ enhances the precision and efficacy of complex cardiac ablation procedures in real-time. Their impact is equally crucial in different stages of patient care.

Pricing & Value

Tie

Neither Cleerly ISCHEMIA nor VX1+ provides publicly available pricing information. Without transparency on costs, it is impossible to conduct a head-to-head comparison of their value propositions or determine which offers better pricing.

Enterprise Readiness

Cleerly ISCHEMIA

Cleerly ISCHEMIA explicitly states it is HIPAA compliant and offers a Business Associate Agreement (BAA), which are crucial for enterprise adoption and data security in healthcare. Its web-based deployment with data transfer via VPN or virtual appliance and API integration also demonstrate strong readiness for integration into existing IT infrastructures. VX1+ only states these are 'expected' but not explicitly confirmed in the provided facts.

Innovation

VX1+

While Cleerly ISCHEMIA's non-invasive fractional flow reserve (FFR) estimation and detailed plaque characterization from CCTA are highly innovative for diagnostic pathways, VX1+'s application of AI in real-time during a complex, live interventional cardiac ablation procedure represents a distinct and arguably more challenging frontier in medical AI, directly influencing immediate procedural outcomes.

Support & Docs

Tie

The provided structured facts do not contain any specific information regarding support services or documentation for either Cleerly ISCHEMIA or VX1+. Therefore, it is impossible to differentiate between the two tools on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Cleerly ISCHEMIA	VX1+
Name	Cleerly ISCHEMIA	VX1+
Company	Cleerly	Volta Medical
Description	Cleerly ISCHEMIA is an FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease.	AI-powered software that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia.
Primary Specialty	Cardiology, Radiology	Cardiology
Key Features (Examples)	AI-enabled CCTA analysis, Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination	Real-time manual or automatic annotation of 3D anatomical and electrical maps of the human heart, Identification of spatio-temporal dispersed electrograms (DEs) during AF and AT procedures, AI-driven insights to assist electrophysiologists during ablation procedures

Videos

Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and VX1+.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of Cleerly ISCHEMIA and VX1+?

Cleerly ISCHEMIA is designed to non-invasively determine the likelihood of coronary artery ischemia at a vessel level by analyzing CCTA scans, aiding in personalized diagnosis and treatment planning for heart disease. VX1+ assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia.

Which medical specialties are these AI tools designed to support?

Cleerly ISCHEMIA is primarily intended for use in Cardiology and Radiology. VX1+ is designed to support Cardiology, specifically electrophysiology, during ablation procedures.

How do Cleerly ISCHEMIA and VX1+ integrate with existing clinical systems and workflows?

Cleerly ISCHEMIA is a web-based platform that transfers data via Cleerly Proxy (VPN or virtual appliance) and integrates with PowerScribe via API. VX1+ is a software application that integrates with existing EP recording and 3D mapping systems, such as Boston Scientific LabSystem Pro, GE HealthCare MacLab CardioLab EP Recording System, and Abbott EnSite X 3D mapping system.

What specific AI-driven insights or analyses do these tools provide to assist physicians?

Cleerly ISCHEMIA provides AI-enabled CCTA analysis, non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood determination, coronary plaque characterization, and stenosis severity assessment. VX1+ offers real-time manual or automatic annotation of 3D anatomical and electrical maps, identifies spatio-temporal dispersed electrograms (DEs), and provides AI-driven insights to assist during ablation procedures, including cycle length estimation.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Cleerly ISCHEMIA or VX1+

Backers

Who funded each tool's parent company.